Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGC018 in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
NCT06227546Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of vobramitamab duocarmazine in small cell lung cancer (SCLC), sponsored by Georgetown University. Started Apr 2024; status: active, not recruiting.
02
Drugs
vobramitamab duocarmazine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06227546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227546.